

Cost Utility Analysis of a Digital Peer Navigation Intervention for Patients after Treatment for Prostate Cancer

Elizabeth Yiminum Yusuf^{1,2}, Therese Servito¹, Marie Lan¹, Peter Coyte¹, Arminee Kazanjian³, Robin Urquhart⁴, Rebecca Hancock-Howard¹, Jackie Bender^{1,2}

¹ Dalla Lana School of Public Health, Institute of Health Policy Management and Evaluation, University of Toronto; ² Princess Margaret Cancer Centre, UHN, ³ University of British Columbia, ⁴ Dalhousie University

INTRODUCTION

- Patients with **prostate cancer** (PC) often lack support and face **barriers to care** when dealing with treatment side effects, thus impairing quality of life^{1,2}.
- Patient navigation is the broad term for all types of navigation while peer navigation utilises navigators that are trained peers and are sometimes paid for this position ⁴
- Patient navigation** can improve access to care, provide personalized support and improve quality of life³. However, less is known about the impact of peer navigation.



RATIONALE AND OBJECTIVES

- Previous studies have demonstrated the effectiveness of patient navigation involving professional or clinical navigators³; there is minimal economic evidence on peer-led navigation (PN).
- True North Peer Navigation (PN) uses a digital app to match PC patients with a volunteer peer navigator who has experienced PC and is trained to help them access care and support. Its effectiveness has recently been shown in a randomized trial ⁴.
- This study aims to evaluate the cost-utility of True North PN compared to an active wait-list control plus, online resource library, from a healthcare payer perspective.

METHODS

- A Markov model was developed to compare the two interventions, consisting of 4 patient activation levels (1 - 4) and a death state.
- The Patient Activation Measure (PAM) is a scale that assesses a person’s knowledge, skills, and confidence in managing their health. It reflects 4 progressive stages of activation, from recognising the importance of one’s role to sustaining health behaviours even under stress ⁶.
- The time horizon was 2 years; this was selected as most side effects get resolved within this timeline with treatments, and the cycle length was 3 months. Costs and outcomes were discounted at an annual rate of 1.5% in line with Canada Drug Agency guidelines.
- Transition probabilities and utilities were informed by an unpublished randomised controlled trial (ID: NCT05041504).
- All costs were sourced from program data and public databases, combining participant-reported healthcare use with unit costs from OHIP, CIHI, and professional associations for physician, surgical, and allied health services.
- One-way deterministic, scenario, and probabilistic sensitivity analyses were performed to evaluate uncertainty and test assumptions.

MODEL AND RESULTS



Condition	Cost (\$CAD)	QALYs	ICER (\$/QALY)
Intervention	4,882	6.69	
Control	4,565	6.65	
Incremental	317	0.034	9,283

RESULTS

- While True North PN was more costly (\$4,882 vs. \$4,565 per person), it yielded more QALYs (6.69 vs. 6.65) when compared to the control group, resulting in an ICER of \$9,283 per QALY gained.
- The incremental QALY gain (0.034) indicates a small but positive improvement in health outcomes
- The probability that True North PN was cost-effective at a willingness-to-pay threshold (WTP) of \$50,000/QALY was 55%.

REFERENCES

- Canadian Partnership Against Cancer. Prostate Cancer Control in Canada: A System Performance Spotlight Report. Toronto, ON; 2015
- Chen RC, Basak R, Meyer AM, et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA - 2017;317(11):1141-1150.
- Chan RJ, Milch VE, Crawford-Williams F, Agbejule OA, Joseph R, Johal J, et al. Patient navigation across the cancer care continuum: An overview of systematic reviews and emerging literature. CA Cancer J Clin. 2023; 73(6):565-589.
- Bender JL, Flora PK, Soheilipour S, Dirlea M, Maharaj N, Parvin L, Matthew A, Catton C, Jamnicky L, Pollock P, Kwan W, Finelli A, Kazanjian A. Web-Based Peer Navigation for Men with Prostate Cancer and Their Family Caregivers: A Pilot Feasibility Study. Current Oncology 2022;29:4285–4299.
- Canadian Partnership Against Cancer, 2012
- Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26. doi: 10.1111/j.1475-6773.2004.00269.x. PMID: 15230939; PMCID: PMC1361049.

SUMMARY AND CONCLUSIONS

- A digital peer navigation program is cost-effective from a Canadian healthcare payer’s perspective, with an ICER of \$9,282/QALY and at a WTP threshold of \$50,000/QALY.
- A 55% probability of cost-effectiveness at a \$50,000/QALY threshold suggests moderate evidence that True North PN may be cost-effective, uncertainty in the results remain, and further evaluation may be needed before broad implementation.
- Our study adds to a limited but growing body of evidence on the cost-effectiveness of patient navigation programs, outside the US, as all evidence on the cost-effectiveness of patient navigation to date has been conducted in the US. Particularly with volunteer peer navigators.
- Future studies should assess subgroup benefits, validate findings with larger or longer studies, and explore how to integrate digital peer navigation into routine prostate cancer care.

This research was funded by:

